FDA panel backs peptides over its own scientists
Six of seven compounds clear a reconstituted committee, as questions mount over evidence, access and who benefits. A divided advisory panel to the US Food and Drug Administration voted this week to recommend six of seven reviewed peptides for addition to the list of substances that licensed pharmaci
<p>Six of seven compounds clear a reconstituted committee, as questions mount over evidence, access and who benefits. A divided advisory panel to the US Food and Drug Administration voted this week to recommend six of seven reviewed peptides for addition to the list of substances that licensed pharmaci</p>